Colorectal cancer remains the second commonest cause of cancer death in Western Europe and North America. Each year in the United Kingdom, there are approximately 35000 new cases and 16000 deaths attributable to the disease (Cancerstats, 2004, www.cancerresearchuk.org). Approximately one-fifth of patients will have colorectal liver metastases. Overall survival is poor; even in those patients who undergo potentially curative resection, more than one-third die within 5 years (McArdle and Hole, 2002).

It is increasingly recognised that variations in outcome in cancer patients are not solely determined by the characteristics of the tumour but also by the host-response factors (MacDonald, 2007). It is now accepted that the host systemic inflammatory response can be assessed by examining the changes in the circulating concentrations of acute-phase proteins, such as elevated concentrations of C-reactive protein and low concentrations of albumin (Gabay and Kushner, 1999; McMillan et al, 2001). It is of interest that either singly or combined these factors have been shown to be stage- and performance status-independent prognostic factors in patients with a variety of inoperable cancers (Forrest et al, 2003, 2004; Al Murri et al, 2006; Crumley et al, 2006; Glen et al, 2006; Ramsey et al, 2007). Similarly, singly these factors have been shown to be tumour stage-independent prognostic factors, prior to surgery, in patients with a variety of primary operable cancers including colorectal cancer (Heys et al, 1998; Longo et al, 1998; Nozoe et al, 1998; Longo et al, 2000; Nielsen et al, 2006; McMillan et al, 2003). Furthermore, Wong et al (2007) showed that an elevated C-reactive protein concentration was an independent predictor of survival in patients undergoing potentially curative surgery for colorectal liver metastases. Recently, the combination of C-reactive protein and albumin, known as the Glasgow Prognostic Score (GPS) has been evaluated pre-operatively in patients undergoing potentially curative surgery for colorectal cancer (McMillan et al, 2007).

However, acute-phase proteins are just one aspect of the systemic inflammatory response (Gabay and Kushner, 1999). There are cellular components of the systemic inflammatory response such as neutrophils, lymphocytes, monocytes and platelets that have been reported to have prognostic value in patients with a variety of common solid tumours (Riesco, 1970;
Bruckner et al, 1982; Vigano et al, 2000; Maltoni et al, 2005; Hauser et al, 2006). Therefore, it may be that the components of the whole-blood differential white cell count either singly or in combination may have prognostic value in patients with either primary operable or metastatic colorectal cancer. Indeed, Walsh et al (2005) reported that the neutrophil/lymphocyte ratio had prognostic value in patients undergoing surgery for colorectal cancer. However, it is known whether such white cell measures offer prognostic value that is independent of tumour stage or superior to the combination of C-reactive protein and albumin (GPS).

Therefore, the aim of the present study was to examine the relationship between selected markers of the systemic inflammatory response, treatment and survival in patients with primary operable or synchronous unresectable colorectal cancer.

PATIENTS AND METHODS

Patients

Patients with histologically proven colorectal cancer who, on the basis of laparotomy findings and/or preoperative abdominal-computed tomography, were considered to have undergone a potentially curative resection or had synchronous unresectable liver metastases and had routine laboratory measurement of white cell, neutrophil, lymphocyte, monocyte and platelet counts, albumin and C-reactive protein, between February 1998 and May 2006 at Glasgow Royal Infirmary were included in the study. The tumours were staged according to the TNM criteria (AJCC, 2002). Patients who had clinical evidence of infection or other inflammatory condition were excluded from the study.

The extent of deprivation was defined using the Carstairs deprivation index (Carstairs and Morris, 1991). This is an area-based measure derived from the 1991 census, using the postcode of residence at diagnosis, which divides the score into a seven-point index. For illustrative purposes, the results are presented by amalgamating the seven categories into three groups: affluent (categories 1 and 2), intermediate (categories 3–5) and deprived (categories 6 and 7). The Carstairs deprivation index has been extensively utilised in cancer patients and is particularly appropriate for use in the central belt of Scotland (Hole and McArdle, 2002).

Patients with synchronous colorectal liver metastases either had their primary colorectal cancer excised, stented, or by-passed due to obstructive symptoms or chemo/radiotherapy.

The study was approved by the Research Ethics Committee, Royal Infirmary, Glasgow.

Methods

The coefficient of variation for the routine laboratory measurements of absolute white cell, neutrophil, lymphocyte, monocyte and platelet counts, albumin and C-reactive protein, over the range of measurement, was less than 10% as established by routine quality control procedures. The limit of detection of the assay was a C-reactive protein concentration lower than 6 mg l\(^{-1}\).

The GPS was constructed as previously described (Forrest et al, 2003). Briefly, patients with both an elevated C-reactive protein (\(>10\) mg l\(^{-1}\)) and hypoalbuminaemia (\(<35\) g l\(^{-1}\)) were allocated a score of 2. Patients in whom only one of these biochemical abnormalities was present were allocated a score of 1. Patients in whom neither of these abnormalities was present were allocated a score of 0.

Recently, however, this has been modified based on evidence that hypoalbuminaemia, in patients without an elevated C-reactive protein concentration, had no significant association with cancer-specific survival. Therefore, patients with an elevated C-reactive protein were assigned a modified GPS score (mGPS) of 1 or 2 depending on the absence or presence of hypoalbuminaemia (McMillan et al, 2007).

Statistics

Grouping of the variables white cell, neutrophil, lymphocyte, monocyte and platelet counts was carried out using standard thresholds (Riesco, 1970; Bruckner et al, 1982; Vigano et al, 2000; Maltoni et al, 2005; Hauser et al, 2006). Survival analysis of the group variables was performed using the Cox proportional hazard model. Deaths up to the end of April 2007 were included in the analysis. Multivariate survival analysis, including all significant covariates (\(P<0.05\) to account for multiple comparisons) was performed using a stepwise backward procedure to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding \(P\)-value had to be greater than 0.05. The relationships between the mGPS and other variables were analysed using the Mantel–Haenszel \(X^2\) test for trend as appropriate. Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).

RESULTS

Two patient groups were studied: 149 patients who underwent potentially curative resection for colorectal cancer and 84 patients who had synchronous unresectable liver metastases (Table 1). Overall, the majority of patients were aged 65 years or more, were male, were deprived, had colonic tumours and had TNM stage I/II tumours. The majority of patients had white cell, neutrophil, lymphocyte, monocyte and platelet counts and albumin concentrations in the normal range. In contrast, C-reactive protein and thus the mGPS were elevated in the majority of patients.

Patients with synchronous unresectable liver metastases had higher white cell, neutrophil, lymphocyte and monocyte counts (all \(P<0.01\)) and C-reactive and mGPS (both \(P<0.001\)) compared with primary operable disease (Table 1). On follow-up more patients with synchronous unresectable liver metastases died of their cancer (\(P<0.001\)).

The relationship between clinicopathological characteristics, systemic inflammatory response and survival in patients with primary operable cancer is shown in Table 2. The minimum follow-up was 36 months, maximum 73 months; the median follow-up of the survivors was 48 months. During the follow-up period 45 patients died, 20 patients of their cancer and 25 of intercurrent disease. On univariate survival analysis, age (\(P<0.01\), TNM stage (\(P<0.05\)), white cell (\(P<0.001\)), neutrophil (\(P<0.01\)), monocyte (\(P<0.01\)), and platelet (\(P<0.05\)) counts and mGPS (\(P<0.001\)) were significantly associated with overall survival (Table 2). On multivariate survival analysis of these significant variables only age (HR 1.74, 95% CI 1.19–2.56, \(P=0.005\)), TNM stage (HR 2.28, 95% CI 1.36–3.82, \(P=0.002\)), monocyte count (HR 3.11, 95% CI 1.42–6.82, \(P=0.005\)) and mGPS (HR 2.08, 95% CI 1.32–3.28, \(P=0.002\)) were independently associated with overall survival.

On univariate survival analysis, TNM stage (\(P<0.05\)), white cell (\(P<0.01\)), neutrophil (\(P<0.01\)), monocyte (\(P<0.01\)), and platelet (\(P<0.05\)) counts and mGPS (\(P<0.05\)) were significantly associated with poorer cancer-specific survival (Table 2). On multivariate survival analysis of these significant variables, only TNM stage (HR 3.75, 95% CI 1.54–9.17, \(P=0.004\)), monocyte count (HR 3.79, 95% CI 1.29–11.12, \(P=0.015\)) and mGPS (HR 2.21, 95% CI 1.11–4.41, \(P=0.024\)) were independently associated with cancer-specific survival. When mGPS was excluded from the model, on multivariate analysis only TNM stage (HR 2.49, 95% CI 1.11–5.61, \(P=0.0274\)) and white cell count (HR 2.22, 95% CI 1.28–3.84,
Table 1  The relationship between clinicopathological characteristics, the systemic inflammatory response and survival in patients with primary operable colorectal cancer; univariate analysis

| Primary operable (n = 149) | Synchronous unresectable (n = 84) | P-value |
|----------------------------|----------------------------------|---------|
| **Age (≤65/65–74/> 75 years)** | 48/52/49 | 34/27/23 | 0.215 |
| **Sex (male/female)**       | 81/68  | 48/36  | 0.683 |
| **Deprivation (1–2/3–5/6–7)** | 5/66/78 | 7/33/44 | 0.981 |
| **Tumour site (colon/rectum)** | 83/66  | 52/32  | 0.358 |
| **TNM Stage (I/II/III/IV)**  | 22/62/65/0 | 0/0/0/84 | <0.001 |
| **White cell count (≤8.5/8.5–11/> 11 × 10^9 l^{-1})** | 82/40/17 | 30/27/27 | <0.001 |
| **Neutrophil count (≥7.5/> 7.5 × 10^9 l^{-1})** | 129/20  | 49/35  | <0.001 |
| **Lymphocyte count (≥3.0/> 3.0–10/> 10 × 10^9 l^{-1})** | 7/13/11 | 26/66/16 | 0.008 |
| **Neutrophil/lymphocyte ratio (≤5/> 5)** | 124/25  | 48/36  | <0.001 |
| **Monocyte count (≤0.9/> 0.9 × 10^9 l^{-1})** | 132/17  | 61/23  | 0.002 |
| **Platelet count (≤400/> 400 × 10^9 l^{-1})** | 117/32  | 55/27  | 0.057 |
| **C-reactive protein (≤10/> 10 mg l^{-1})** | 88/61  | 17/64  | <0.001 |
| **Albumin (≥35/> 35 g l^{-1})** | 135/14  | 55/29  | <0.001 |
| **mGPS (0/1/2)** | 88/48/13 | 17/44/23 | <0.001 |
| **Alive**                   | 104     | 13     |        |
| **Dead**                    | 20      | 71     |        |
| **Non-cancer**              | 25      | 0      | <0.001 |

TNM = tumour, node, metastases; mGPS = modified Glasgow Prognostic Score. *Individual deprivation categories were used in the statistical analysis.

Table 2  The relationship between clinicopathological characteristics, the systemic inflammatory response and survival in patients with colorectal cancer; univariate analysis

| Overall survival | Cancer-specific survival |
|------------------|-------------------------|
| **Patients (n = 149)** | **Hazard ratio (95% CI)** | **P-value** | **Hazard ratio (95% CI)** | **P-value** |
| **Age (≤65/> 65–74/> 75 years)** | 1.65 (1.13–2.39) | 0.009 | 1.48 (0.85–2.57) | 0.166 |
| **Sex (male/female)** | 0.76 (0.42–1.38) | 0.371 | 1.15 (0.48–2.75) | 0.762 |
| **Deprivation (1–2/3–5/6–7)** | 0.98 (0.82–1.16) | 0.799 | 0.87 (0.68–1.13) | 0.298 |
| **Tumour site (colon/rectum)** | 0.96 (0.54–1.74) | 0.903 | 0.80 (0.33–1.95) | 0.621 |
| **TNM Stage (I/II/III)** | 1.79 (1.13–2.85) | 0.014 | 2.63 (1.19–5.80) | 0.016 |
| **Neo-adjuvant therapy (yes/no)** | 0.55 (0.13–2.25) | 0.402 | 1.30 (0.30–5.62) | 0.722 |
| **Adjuvant therapy (yes/no)** | 0.89 (0.48–1.66) | 0.718 | 1.79 (0.74–4.29) | 0.195 |
| **White cell count (≤8.5/> 8.5–11/> 11 × 10^9 l^{-1})** | 1.92 (1.32–2.81) | 0.001 | 2.40 (1.38–4.16) | 0.002 |
| **Neutrophil count (≤7.5/> 7.5 × 10^9 l^{-1})** | 2.90 (1.46–5.73) | 0.002 | 3.77 (1.44–9.82) | 0.007 |
| **Lymphocyte count (≥3.0/> 3.0–10/> 10 × 10^9 l^{-1})** | 0.72 (0.29–1.80) | 0.484 | 0.30 (0.09–1.01) | 0.053 |
| **Monocyte count (≥0.9/> 0.9 × 10^9 l^{-1})** | 2.86 (1.38–5.95) | 0.005 | 3.78 (1.37–10.40) | 0.010 |
| **Platelet count (≥400/> 400 × 10^9 l^{-1})** | 2.10 (1.12–3.95) | 0.022 | 2.53 (1.01–6.35) | 0.048 |
| **Neutrophil/lymphocyte ratio (≤5/> 5)** | 1.68 (0.83–3.39) | 0.150 | 1.49 (0.50–4.45) | 0.479 |
| **mGPS (0/1/2)** | 2.07 (1.35–3.16) | 0.001 | 2.01 (1.06–3.80) | 0.032 |

TNM = tumour, node, metastases; mGPS = modified Glasgow Prognostic Score; CI = confidence interval. Individual deprivation categories were used in the statistical analysis.

P = 0.004) were independently associated with cancer-specific survival.

The relationship between clinicopathological characteristics, systemic inflammatory response and survival in patients with unresectable colorectal liver metastases is shown in Table 3. The minimum follow-up was 6 months, maximum 73 months; the median follow-up of the survivors was 12 months. A total of 71 (85%) patients died of their disease during the follow-up period. On univariate analysis, age (P<0.05), any single liver metastasis >5 cm (P<0.01), extra-hepatic disease (P<0.05), chemotherapy (P<0.0001) and mGPS (P≤0.001) were significantly associated with poorer cancer-specific survival. Table 3. On multivariate analysis of these significant variables, including treatment, only single liver metastasis >5 cm (HR 1.78, 95% CI 0.99–3.21, P = 0.054), extra-hepatic disease (HR 2.09, 95% CI 1.05–4.17, P = 0.036), chemotherapy treatment (HR 2.40, 95% CI 1.82–3.17, P<0.001) and mGPS (HR 1.44, 95% CI 1.01–2.04, P = 0.043) were independently associated with poorer cancer-specific survival. When mGPS was excluded from the model, on multivariate analysis only single liver metastasis > 5 cm (HR 1.97, 95% CI 1.12–3.47, P = 0.018), extra-hepatic disease (HR 2.02, 95% CI 1.02–4.01, P = 0.043) and chemotherapy treatment (HR 2.29, 95% CI 1.76–2.98, P<0.001) were independently associated with cancer-specific survival.

The relationship between the mGPS and clinicopathological characteristics in all colorectal cancer patients is shown in Table 4. An increase in the mGPS was associated with an increase in TNM stage (P<0.001), higher white cell (P<0.001), neutrophil (P<0.001), monocyte (P<0.01) and platelet (P<0.001) counts and also the neutrophil/lymphocyte ratio (P<0.001). An increase in the mGPS was associated with a lower lymphocyte count (P<0.01).

The relationship between TNM stage, the mGPS and cancer-specific survival is shown in Figures 1 and 2 respectively.
DISCUSSION

In the present study a number of cellular components of the systemic inflammatory response were associated with cancer-specific survival in patients with colorectal cancer and therefore confirm previous work in other tumour types. However, compared with a score (mGPS) based on the acute-phase proteins, C-reactive protein and albumin, these cellular components of the white cell count, did not consistently have independent prognostic value.

Table 3  The relationship between clinicopathological characteristics, the systemic inflammatory response and cancer-specific survival in patients with synchronous unresectable colorectal liver metastases; univariate analysis

| Characteristic                                  | Hazard ratio (95% CI) | P-value |
|-------------------------------------------------|-----------------------|---------|
| Age (<65/65 – 74/> 75 years)                    | 34/27/23              | 1.47 (1.08 – 2.00) | 0.0139 |
| Sex (male/female)                               | 48/36                 | 1.13 (0.70 – 1.82) | 0.6176 |
| Deprivation (1 – 2/3 – 5/6 – 7)*                | 7/33/44               | 0.98 (0.85 – 1.12) | 0.7336 |
| Tumour site (colon/rectum)                      | 52/32                 | 1.14 (0.70 – 1.85) | 0.6048 |
| Emergency presentation (no/yes)                 | 15/5                  | 1.56 (0.74 – 3.27) | 0.2423 |
| No. of liver metastases (<5/5 > 5 cm)           | 36/58                 | 2.19 (1.30 – 3.67) | 0.0030 |
| Extra-hepatic disease (no/yes)                  | 64/20                 | 2.06 (1.16 – 3.67) | 0.0140 |
| Therapy: chemotherapy+primary resected or stent/chemotherapy alone/primary resected/no active treatment | 28/20/23/13 | 2.16 (1.71 – 2.73) | <0.0001 |
| White cell count (<8.5/8.5 – 11/> 11 x 10^9 l^-1) | 30/27/27              | 1.31 (0.99 – 1.75) | 0.0631 |
| Neutrophil count (<7.5/> 7.5 x 10^9 l^-1)       | 49/35                 | 1.57 (0.98 – 2.53) | 0.0627 |
| Lymphocyte count (>3.0/3.0 – 3.0/1.0 x 10^9 l^-1) | 2/66/16/16            | 1.65 (0.93 – 2.93) | 0.0864 |
| Monocyte count (<0.9/> 0.9 x 10^9 l^-1)         | 6/23                  | 1.32 (0.77 – 2.25) | 0.3122 |
| Platelet count (<400/> 400 x 10^3 l^-1)         | 55/27                 | 1.36 (0.82 – 2.25) | 0.2338 |
| Neutrophil/lymphocyte ratio (>5/> 5)            | 48/36                 | 1.35 (0.84 – 2.16) | 0.0030 |
| mGPS (0/1/2)                                    | 17/44/23              | 1.46 (1.05 – 2.03) | 0.0243 |

mGPS = modified Glasgow Prognostic Score; CI = confidence interval. *Individual deprivation categories were used in the statistical analysis.

Table 4  The relationship between the mGPS and clinicopathological characteristics in patients with colorectal cancer (n = 233)

| mGPS 0 (n = 105) | mGPS 1 (n = 92) | mGPS 2 (n = 36) | P-value |
|------------------|----------------|----------------|---------|
| Age (<65/65 – 74/> 75 years) | 37/38/30 | 34/30/28 | 11/11/14 | 0.431 |
| Sex (male/female) | 62/43 | 47/45 | 20/16 | 0.487 |
| Deprivation (1 – 2/3 – 5/6 – 7)* | 6/45/54 | 4/41/47 | 2/13/21 | 0.584 |
| Tumour site (colon/rectum) | 5/4/51 | 59/33 | 22/14 | 0.142 |
| TNM Stage (I/II/III/IV) | 15/20/30/32 | 6/25/17/44 | 1/7/5/23 | <0.001 |
| White cell count (<8.5/8.5 – 11/> 11 x 10^9 l^-1) | 75/23/7 | 37/33/22 | 10/11/15 | <0.001 |
| Neutrophil count (<7.5/> 7.5 x 10^9 l^-1) | 96/9 | 65/27 | 17/19 | <0.001 |
| Lymphocyte count (>3.0/3.0 – 3.0/1.0 x 10^9 l^-1) | 3/97/5 | 6/74/12 | 0/26/10 | 0.002 |
| Monocyte count (<0.9/> 0.9 x 10^9 l^-1) | 95/10 | 74/18 | 24/12 | 0.001 |
| Platelet count (<400/> 400 x 10^3 l^-1) | 93/11 | 62/30 | 17/19 | <0.001 |
| Neutrophil/lymphocyte ratio (<5/> 5) | 96/9 | 6/13 | 15/21 | <0.001 |

TNM = tumour, node, metastases; mGPS = modified Glasgow Prognostic Score. *Individual deprivation categories were used in the statistical analysis.

© 2007 Cancer Research UK

Figure 1  The relationship between TNM stage (I, II, III and IV from top to bottom) and cancer-specific survival in patients with colorectal cancer.

Figure 2  The relationship between mGPS (0, 1 and 2 from top to bottom) and cancer-specific survival in patients with colorectal cancer.
Therefore, it would appear that the mGPS is superior to these cellular components, in particular the neutrophil/lymphocyte ratio, in predicting survival at different tumour stages in patients with colorectal cancer.

The results of the present study may also offer insight into the nature of the relationship between the systemic inflammatory response and survival in patients with primary operable and metastatic unresectable colorectal cancer. A plausible explanation is that an elevated mGPS may reflect compromised acquired immunity as it was associated with an increase in lymphopenia. An alternative explanation is that an elevated mGPS may reflect altered innate immunity as it was also associated with increased numbers neutrophils and monocytes. However, given that higher neutrophil and monocyte counts were more strongly associated with poorer cancer-specific survival this may suggest that of activation of the innate, rather than downregulation of the acquired immune system, is the most important factor in determining poor outcome in patients with colorectal cancer. It may be that downregulation of these innate cell types should targeted in the treatment of patients with colorectal cancer.

With respect to metastatic unresectable disease there is now considerable evidence that chronic activation of the systemic inflammatory response and colorectal cancer survival is that an elevated mGPS may reflect compromised acquired immunity as it was associated with an increase in lymphopenia. An alternative explanation is that an elevated mGPS may reflect altered innate immunity as it was also associated with increased numbers neutrophils and monocytes. However, given that higher neutrophil and monocyte counts were more strongly associated with poorer cancer-specific survival this may suggest that of activation of the innate, rather than downregulation of the acquired immune system, is the most important factor in determining poor outcome in patients with colorectal cancer. It may be that downregulation of these innate cell types should targeted in the treatment of patients with colorectal cancer.

ACKNOWLEDGEMENTS

The authors acknowledge the interest and encouragement of Mr Ian G Finlay.

REFERENCES

Al Murri AM, Bartlett JN, Canney PA, Doughty JC, Wilson C, McMillan DC (2006) Evaluation of inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94: 227–230

American Joint Committee on Cancer (2002) Colon and rectum. In Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Mokrrow M (eds) AJCC Cancer Staging Manual, 6th edn, pp 113–124. New York, NY: Springer

Blumberg RM, Stockler MR, Tattersall MH (2006) Prognostic factors in resectable colorectal cancer. Surgery 139: 637–641

Carstairs V, Morris R (1991) Deprivation and health in Scotland. Aberdeen: University Press

Crummy LB, McMillan DC, McKernan M, McDonal AC, Sturt RC (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 94: 637–641

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89: 1028–1030

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90: 1704–1706

Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454

Glen F, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6: 450–453

Hauser CA, Stockler MR, Tattersall MH (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 14: 999–1011

Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a useful determinant of prognosis for patients with metastatic colorectal cancer. JAMA 274: 1004–1006

Carstairs V, Morris R (1991) Deprivation and health in Scotland. Aberdeen: University Press

Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006) Evaluation of an inflammation-based prognostic score in patients with metastatic colorectal cancer. Br J Cancer 94: 157–162

Kotler DP (2000) Cachexia. Ann Intern Med 133: 622–634

Longo WE, Virgo KS, Johnson FE, Oprian CA, Vernava AM, Wade TP, Phelan MA, Henderson WG, Daley J, Khiuri SF (2000) Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum 43: 83–91

Longo WE, Virgo KS, Johnson FE, Wade TP, Vernava AM, Phelan MA, Henderson WG, Daley J, Khiuri SF (1998) Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program. Ann Surg 228: 64–70

MacDonald N (2007) Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 5: 157–162

Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, glare P, Nabal M, Vignano A, Larkin P, De Conno F, Hanks G, Kaasa S, Steering Committee of the European Association for Palliative Care (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23: 6240–6248

McMillan DC, Hole DJ (2002) Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 86: 331–335

McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215–219

McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22: 881–886

McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41: 64–69

Nielsen HJ, Christensen JI, Sorensen S, Moesaard F, Brunner N (2000) Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX50 Colorectal Cancer Study Group. Ann Surg Oncol 7: 617–623

Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335–338

Ramsay S, Lamb GW, Aitichison M, Graham J, McMillan DC (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109: 205–212

Riesco A (1970) Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135–140

Vignano A, Bruera E, Jiangri GS, Newman SC, Fields AL, Suarez-Almazor ME (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160: 861–868

Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181–184

Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR, Tooogood GJ, Lodge JP (2007) C-reactive protein as a predictor of survival following curative resection for colorectal liver metastases. Br J Cancer 96: 222–225

Systemic inflammatory response and colorectal cancer survival

EF Leitch et al

British Journal of Cancer (2007) 97(9), 1266 – 1270

© 2007 Cancer Research UK